ALKERMES | ALKS - Ebit

Aktienkurs
33.31
Täglich Wechseln
-0.60 -1.77%
Monatlich
13.42%
Jährlich
19.65%
Q2 Prognose
32.32




Ebit Veränderung Datum
AbbVie USD 5.81B 4.36B 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 157M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 8.99B 1.57B 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 6.62B 1.51B 2026-03
Malin Corporation EUR -1.1M 300K 2024-12
Merck USD 6.24B 1.32B 2025-12
Minerva Neurosciences USD -4.37M 1.71M 2024-09
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Otsuka Holdings JPY 67.25B 101.57B 2025-12
Ovoca Bio EUR -1.16M 4.48M 2025-06
Pfizer USD 4.65B 71M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12